abstract |
The present invention relates to a novel regimen for treating rheumatoid arthritis. A therapeutically effective amount of an IL-17 antagonist, such as an IL-17 binding molecule (eg, an IL-17 antibody or antigen binding fragment thereof, eg, secukinumab) or an IL-17 receptor binding molecule (eg, , IL-17 antibody or antigen-binding fragment thereof). [Selection figure] None |